Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Allergy and Asthma Reports
Published in: Current Allergy and Asthma Reports 6/2013

01-12-2013 | Hot Topic

Lupus Nephritis: Review of the Literature

Authors: Adeel Zubair, Marianne Frieri

Published in: Current Allergy and Asthma Reports | Issue 6/2013

Login to get access

Abstract

Physicians in practice should be knowledgeable regarding several aspects of autoimmune disorders, especially systemic lupus erythematosus (SLE) and lupus nephritis. These disorders can present to the clinician’s clinic and private office regardless of their speciality. This review will discuss various aspects of SLE, its mechanisms of disease, role of accelerated atherosclerosis, proinflammatory cytokines, and therapeutic approaches. The role of vascular endothelial growth factor in which and plasma levels have been associated with disease activity, classification of severity, and diagnosis of lupus nephritis is addressed. Current treatment options, prognosis, and future therapeutic approaches and common side effects are also discussed.
Literature
1.
Smyth A, Oliveira GH, Lahr B, et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol. 2010;5(11):2060–8.PubMedCrossRef
2.
de Zubiria Salgado A, Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmun Dis. 2012;2012:849684.
3.
Bastian HM, Roseman JM, McGwin G Jr, et al. Systemic lupus erythematosus in three ethic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus. 2002;11(3):152–60.
4.
•• Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol. 2013;110:228–32. This article lists the mechanisms of SLE for the clinician, documenting complex interactions and listing important literature in peer-reviewed journals on the clinical and immunologic features, pathogenesis, epidemiology, laboratory evaluation, and treatment of SLE.PubMedCrossRef
5.
•• Frieri M. Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. Curr Allergy Asthma Rep. 2012;12(1):25–32. This paper discusses disturbances in gene expression involved in lipid transport and atheroma promotion and provides evidence of the immune system in accelerated atherosclerosis in SLE, the role of selected proinflammatory cytokines, and therapeutic approaches.PubMedCrossRef
6.
Kaplan J, Anand P, Frieri M. Rash, drug hypersensitivity and autoimmunity in a 20 year old. Ann Allergy Asthma Immunol. 2005;95:111–4.PubMedCrossRef
7.
Horne NS, Narayan AR, Young RM, Frieri M. Toxic epidermal necrolysis in systemic lupus erythematosus. Autoimmun Rev. 2006;5:160–4.PubMedCrossRef
8.
Frieri M. Identification of masqueraders of autoimmune disease in the office. Allergy Asthma Proc. 2003;24(6):421–9.PubMed
9.
•• Zubair A, Frieri M. NF-κB and systemic lupus erythematosus:examining the link .JNephrolD-13-00003R1, online on 6/14/2013. This paper reviews the link between NF-κB and SLE, including B-cell development, signaling, and cytokines which play a crucial role in the pathogenesis of SLE and T-cell development and activation. The roles of dendritic cells polymorphisms, NF-κB, which are linked with SLE and Toll-like receptors, are also discussed.
10.
Gordon C, Jayne D, Pusey C, et al. European consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009;18(3):257–63.PubMedCrossRef
11.
Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10(2):413–24. activity.PubMed
12.
Weening JJ, D’Agati VD, Schwartz M, et al. The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited. J Am Soc Nephrol. 2004;15(2):241–50.PubMedCrossRef
13.
Avihingsanon Y, Hirankarn N. Major lupus organ involvement: severe lupus nephritis. Lupus. 2010;19(12):1391–8.PubMedCrossRef
14.
Navarro C, Candia-Zúñiga L, Silveira LH, et al. Vascular endothelial growth factor plasma levels in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Lupus. 2002;11(1):21–4.PubMedCrossRef
15.
Feliers D. Vascular endothelial growth factor as a prognostic marker of lupus nephritis. Kidney Int. 2009;75(12):1251–3.PubMedCrossRef
16.
Zhu L, Shi S, Liu LT, et al. Increased plasma sVCAM-1 is associated with severity in IgA nephropathy. BMC Nephrol. 2013;14:21.PubMedCrossRef
17.
Yedowitz JC, Frieri M. Cytokine and growth factor production from chlamydia pneumoniae hsp 60 stimulated human aortic endothelial cells in the presence of simvastatin. Ann Allergy Asthma Immunol. 2009;102:P113.
18.
Law ST, Ma KM, Li KK. Clinical characteristics of concurrent and sequentially presented lupus-related protein-losing enteropathy: what are their differences? Rheumatol Int. 2013;33(1):85–92.PubMedCrossRef
19.
Awazawa R, Yamamoto Y, Mine Y, et al. Systemic lupus erythematosus complicated with protein-losing enteropathy: a case report and review of the published works. J Dermatol. 2012;39(5):454–61.PubMedCrossRef
20.
Chang YS, Lai CC, Chen WS, et al. Protein-losing enteropathy and premature ovarian failure in a young woman with systemic lupus erythematosus. Lupus. 2012;21(11):1237–9.PubMedCrossRef
21.
Law ST, Ma KM, Li KK. The clinical characteristics of lupus related protein-losing enteropathy in Hong Kong Chinese population: 10 years of experience from a regional hospital. Lupus. 2012;21(8):840–7.PubMedCrossRef
22.
Akkina SBK, Frieri M. Systemic lupus erythematosus, protein losing enteropathy & autoimmune hemolytic anemia. Ann Allergy Asthma Immunol. 2012;109:77a. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.CrossRef
23.
Mosca M, Tani C, Aringer M, et al. League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269–74.PubMedCrossRef
24.
Hara M, Nemoto T, Hijima T, et al. A case of IgA nephropathy associated with mycosis fungoides that developed into rapidly progressive glomerulonephritis. Clin Nephrol. 2013;79(2):161–5.PubMedCrossRef
25.
Wu G, Peng YM, Liu FY et al. The role of memory B cell in tonsil and peripheral blood in the clinical progression of IgA nephropathy. Hum Immunol. 2013;74(6):708–12.
26.
Akkina S, Frieri M. Stable IgA nephropathy post renal transplantation on immune suppressive therapy. Ann Allergy Asthma Immunol. 2012;109:302a.
27.
Lee H, Kim DK, Oh K, et al. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases. Am J Nephrol. 2013;37(1):74–83.PubMedCrossRef
28.
•• Frieri M, Samih MA, Dzhindzhikhashvili M, Liu H, et al. Toll-like receptor 9 and vascular endothelial growth factor levels in human kidneys from lupus nephritis patients. J Nephrol. 2012;25(6):1041–6. This is the first study that investigated combined expression of TLR9 and VEGF, which could be an important tool for understanding the role of TLR9 and VEGF in lupus nephritis with insights into the early detection and targeted treatment of this disease.PubMedCrossRef
29.
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797–808. This report, developed using validated guidelines methodology, represents the American College of Rheumatology’s recommendations for the case identification, treatment, and monitoring of lupus nephritis.CrossRef
30.
31.
Markowitz GS, D’Agati VD. Classification of lupus nephritis. Curr Opin Nephrol Hypertens. 2009;18(3):220–5.PubMedCrossRef
32.
Frieri M, Akkina SA. Case of Persistent Eosinophilia in Lupus Nephritis. P108. Ann Allergy Asthma Immunol. 2011;107:P108.
33.
Giannakakis K, Faraggiana T. Histopathology of lupus nephritis. Clin Rev Allergy Immunol. 2011;40(3):170–80.PubMedCrossRef
34.
Sada KE, Makino H. Usefulness of ISN/RPS classification of lupus nephritis. J Korean Med Sci. 2009;Suppl:S7–10.
35.
Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr. 2010;99(7):967–74.PubMedCrossRef
36.
•• Mok C.C. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol, 2010;638413. Novel biomarkers are necessary to enhance the diagnostic accuracy and sensitivity of lupus renal disease, prognostic stratification, monitoring of treatment response, and detection of early renal flares. This paper reviews promising biomarkers that have recently been evaluated in longitudinal studies of lupus nephritis.
37.
Canetta PA, Bomback AS, Radhakrishnan J. Treating lupus in the kidney: where are we now, and where are we going? Discov Med. 2011;12(65):341–9.PubMed
38.
39.
40.
Yee CS, Gordon C. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350(24):2518–20. author reply 2518-2520.PubMedCrossRef
41.
Dolff S, Berden JH, Bijl M. Treatment of lupus nephritis. Expert Rev Clin Immunol. 2010;6(6):901–11.PubMedCrossRef
42.
Alshayeb H, Wall BM, Gosmanova EO. Treatment of proliferative and membranous lupus nephritis: review of key clinical trials. Am J Med Sci. 2012;343(1):86–90.PubMedCrossRef
43.
Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69(12):2083–9.PubMedCrossRef
44.
Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology (Oxford). 2010;49(1):128–40.CrossRef
45.
Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235–44.PubMedCrossRef
46.
Lee YH, Woo JH, Choi SJ, et al. Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis. Lupus. 2010;19(6):703–10.PubMedCrossRef
47.
48.
Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028–35.PubMedCrossRef
49.
Zeher M, Doria A, Lan J, et al. Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis. Lupus. 2011;20(14):1484–93.PubMedCrossRef
50.
El-Shafey EM, Abdou SH, Shareef MM. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients? Clin Exp Nephrol. 2010;14(3):214–21.PubMedCrossRef
51.
Allen BC, Mohammed TL, Tan CD, et al. Metastatic melanoma to the heart. Curr Probl Diagn Radiol. 2012;41(5):159–64.PubMedCrossRef
52.
Navaneethan SD, Viswanathan G, Strippoli GF. Treatment options for proliferative lupus nephritis: an update of clinical trial evidence. Drugs. 2008;68(15):2095–104.PubMedCrossRef
53.
Bargman JM. How did cyclophosphamide become the drug of choice for lupus nephritis? Nephrol Dial Transplant. 2009;24(2):381–4.PubMedCrossRef
54.
Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69–78.PubMedCrossRef
55.
Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89(4):227–35.CrossRef
56.
Laskari K, Mavragani CP, Tzioufas AG, et al. Mycophenolate mofetil as maintenance therapy for proliferative lupus nephritis: a long-term observational prospective study. Arthritis Res Ther. 2010;12(6):R208.PubMedCrossRef
57.
Rabrenovic V, Poskurica M, Kovacevic Z, et al. Treatment of lupus nephritis by mycophenolate mofetil. Kidney Blood Press Res. 2010;33(4):297–303.PubMedCrossRef
58.
• Radhakrishnan J, Moutzouris DA, Ginzler EM, et al. Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney Int. 2010;77(2):152–60. This study pools analyses of two large randomized controlled multicenter trials of patients with diverse ethnic and racial background who had pure class V disease. Tthe response to mycophenolate mofetil as induction treatment of patients with class V LN appeared to be no different from that of intravenous cyclophosphamide.PubMedCrossRef
59.
•• Arends S, Grootscholten C, Derksen RH, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012;71(6):966–73. Induction treatment with high-dose intravenous cyclophosphamide was superior to azathioprine/methylprednisolone in preventing renal relapses, but other parameters for renal function did not differ. Azathioprine/methylprednisolone can therefore serve as an alternative in patients with proliferative lupus nephritis who wish to avoid the gonadal toxicity of cyclophosphamide Several prognostic factors of long-term renal outcome were identified.PubMedCrossRef
60.
Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886–95.PubMedCrossRef
61.
Khajehdehi P, Zanjaninejad B, Aflaki E, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. J Ren Nutr. 2012;22(1):50–7.PubMedCrossRef
62.
Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011;7(12):718–29.PubMedCrossRef
63.
Masood S, Jayne D, Karim Y. Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus. 2009;18(2):106–15.PubMedCrossRef
64.
Mina R, von Scheven E, Ardoin S, et al. Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2012;64(3):375–83.CrossRef
65.
Aragon E, Chan YH, Ng KT, et al. Good outcomes with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus. 2010;19(8):965–73.PubMedCrossRef
66.
Weng MY, Weng CT, Liu MF. The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus. Clin Rheumatol. 2010;29(7):771–5.PubMedCrossRef
67.
68.
Ogawa H, Kameda H, Amano K, et al. Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus. 2010;19(2):162–9.PubMedCrossRef
69.
Appel AS, Appel GB. An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases. Nat Clin Pract Nephrol. 2009;5(3):132–42.PubMedCrossRef
70.
Jonsdottir T, Sundelin B, Welin Henriksson E, et al. Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits. Ann Rheum Dis. 2011;70(6):1172–3.PubMedCrossRef
71.
Bertsias G, Boumpas DT. Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol. 2008;4(9):464–72.PubMedCrossRef
72.
Tesar V, Hruskova Z. Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol. 2011;7(2):96–109.PubMedCrossRef
73.
Berthier CC, Kretzler M, Davidson A. From the large scale expression analysis of lupus nephritis to targeted molecular medicine. J Data Min Genomics Proteomics 2012;3(3):1000123.
Metadata
Title
Lupus Nephritis: Review of the Literature
Authors
Adeel Zubair
Marianne Frieri
Publication date
01-12-2013
Publisher
Springer US
Published in
Current Allergy and Asthma Reports / Issue 6/2013
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-013-0394-4

Other articles of this Issue 6/2013

Current Allergy and Asthma Reports 6/2013 Go to the issue

Pediatric Allergy and Immunology (JM Portnoy and CE Ciaccio, Section Editors)

Effects of Tobacco Smoke Exposure in Childhood on Atopic Diseases

Pediatric Allergy and Immunology (JM Portnoy and CE Ciaccio, Section Editors)

Primary Mast Cell Disorders in Children

FOOD ALLERGY (D ATKINS, SECTION EDITOR)

Is There a Role for Probiotics in the Prevention or Treatment of Food Allergy?

FOOD ALLERGY (D ATKINS, SECTION EDITOR)

Food-Dependent Exercise-Induced Anaphylaxis: Is Wheat Unique?

FOOD ALLERGY (D ATKINS, SECTION EDITOR)

Food Allergy and Quality of Life: What Have We Learned?

Immune Deficiency and Dysregulation (DP Huston, Section Editor)

Clinical Consequences of Targeting IL-17 and TH17 in Autoimmune and Allergic Disorders